Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[EM]

As expected and anticipated in my precious posts, 20-F released and finally we can find some GREAT updates from the Company.
https://www.sec.gov/Archives/edgar/data/1614744/000121390017004462/f20f2016_kitovpharma.htm

Here the main points:

1) We anticipate that in the near future, we will be filing an international patent application, in partnership with Dexcel Ltd., which is related to pharmaceutical formulations of celecoxib and amlodipine and methods of preparing the same;

2) The Company has engaged an external consultant to assist the Company in applying for regulatory approval of KIT-302 in Europe. As part of this process, the Company is scheduled to meet with regulatory authorities in Sweden and the UK in the second quarter of 2017. At that meeting, the applicability of the Company’s current data for obtaining marketing authorization in various EU countries will be discussed. Following this meeting, a plan will be finalized for obtaining regulatory approval for marketing in EU countries;

3) we have engaged consultants which are assisting us with finding other potential collaboration partners for KIT-302 in various markets world-wide;

4) CMC, including stability testing, completed by Dexcel;

5) Goldman Hirsch Partners Ltd. has a 6,8% stake after TyrNovo acquisition; Roichman and Dexcel still have a position (and for sure, Waymack's JPW PCH LLC).